United States Patent and Trademark Office
- Sales Receipt -

05/18/2006 DWILLIA4 00000002 110980 10635797 Sale Ref: 00000002 DA#: 110980 10635797 01 FC:1814 130.00 DA



### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Jean Rapin, et al.

Serial No.:

10/635,797

**Diseases** 

Filed:

For:

August 5, 2003

Tripeptides and Tripeptide Derivatives for the Treatment of Neuro

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION

Sir:

The owner, Neurotell AG, of the entire interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number 10/635,805, filed on August 5, 2003, as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application," in the event that; any such patent; granted on the pending reference application: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR

# FEE TRANSMITTAL

Attorney Docket No. 10945.105002 (Neuro 101US)

This sheet accompanies a patent application transmitter for the following application:

App. No.:

10/635,797

Inventor(s):

Jean Rapin, Hans Klaus Witzmann, Jean-Marie Grumel, Jacques Gonella

Filing Date:

August 5, 2003

Title:

Tripeptides and Tripeptide Derivatives for the Treatment of Neuro-Degenerative Diseases

The filing fee is calculated as shown below:

#### 1. FILING FEE:

	SMALL ENTITY		LARGE ENTITY	
FOR:	FEE	FEE PAID	FEE	FEE PAID
UTILITY FILING FEE	\$150		\$300	
UTILITY SEARCH FEE	\$250		\$500	
UTILITY EXAMINATION FEE	\$100		\$200	
PROVISIONAL FILING FEE	\$100		\$200	
DESIGN FILING FEE	\$100		\$200	
DESIGN SEARCH FEE	\$50		\$100	
DESIGN EXAMINATION FEE	\$65		\$130	
REISSUE FILING FEE	\$150		\$300	
REISSUE SEARCH FEE	\$250		\$500	
REISSUE EXAMINATION FEE	\$300		\$600	
APPLICATION SIZE FEE (If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).	\$125		\$250	
SUB	TOTAL (1)	Sxxx		Sxxx

### 2. CLAIMS:

### **SMALL ENTITY**

# LARGE ENTITY

FOR:	NO. FILED	NO. EXTRA	RATE	FEE	RATE	FEE
TOTAL CLAIMS	- 20 =	0	x 25 =		x 50 =	
INDEP. CLAIMS	- 3=	0	x 100 =		x 200 =	
MULTIPLE DEPENDENT CLAIM PRESENTED +180 =		+180 =		+360 =		
SUBTOTAL (2)		TOTAL (2)	Sxxx		Sxxx	

### 3. ADDITIONAL FEES:

## SMALL ENTITY

### LARGE ENTITY

FOR:	FEE	FEE PAID	FEE	FEE PAID
LATE FILING, FEE OR OATH	\$65		\$130	
☐ NON-ENGLISH SPECIFICATION	\$130		\$130	
OTHER: Request for Continued Examination				
OTHER 1 Month Extension of Time			120.00	120.00
	SUBTOTAL (3)	\$xxx		\$120.00

# FEE TRANSMITTAL

Page 2

Attorney Docket No. 10945.105002 (Neuro 101US)

TOTAL FILING FEES:

\$120.00

A check is enclosed for the total amount: \$120.00

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 or 1.17, or to credit any overpayment, to Deposit Account No. 11-0980. A duplicate of this document is enclosed.

KING & SPALDING LLP 34th Floor, 1180 Peachtree Street Atlanta, Georgia 30309-3521 Telephone: 404.572.4720

Rv٠

Date: April 4, 2006

Madeline I. Johnston, Attorney for Applicant

Reg. No. 36,174